Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a biopharmaceutical company developing anticoagulant therapies for rare and high-risk patient populations, and its news flow reflects this specialized focus. The CVKD news page on Stock Titan aggregates company announcements, sponsored coverage, and regulatory updates related to its clinical-stage pipeline.
Readers can expect news centered on Cadrenal’s three main assets: VLX-1005, a first-in-class 12-LOX inhibitor in Phase 2 development for heparin-induced thrombocytopenia (HIT); tecarfarin, an oral vitamin K antagonist for chronic use in patients with kidney dysfunction or left ventricular assist devices; and frunexian, a parenteral Factor XIa antagonist positioned for acute hospital settings. Company communications often highlight regulatory designations such as Orphan Drug and Fast Track status, clinical trial progress, and portfolio-expanding transactions.
News items also cover corporate developments, including participation in healthcare investor conferences, partnering outreach, and board-level appointments. Financial updates, such as quarterly results and capital-raising activities disclosed via press releases and Form 8-K filings, provide additional context on how Cadrenal is funding and prioritizing its development programs.
For investors, clinicians, and researchers following the evolution of anticoagulation therapies, the CVKD news feed offers a consolidated view of Cadrenal’s milestones across chronic, acute, and immune-mediated indications. Bookmark this page to review new press releases, sponsored analytical pieces, and SEC-related announcements as they are released, and to track how the company’s strategy and pipeline advance over time.
Cadrenal Therapeutics (NASDAQ: CVKD) announced on Dec 11, 2025 the acquisition of VLX-1005 and related 12-LOX assets from Veralox Therapeutics, adding a late-stage, first-in-class small‑molecule 12‑lipoxygenase inhibitor for heparin‑induced thrombocytopenia (HIT).
VLX-1005 has U.S. Orphan Drug and Fast Track designations, completed two Phase 1 studies showing favorable tolerability, and interim Phase 2 data reporting reductions in thromboembolic events. The release cites a $40 billion global anticoagulation market and an estimated $1 billion HIT market in the US and EU. Veralox may receive upfront, milestone payments and royalties upon commercialization.
Cadrenal Therapeutics (Nasdaq: CVKD) announced on December 1, 2025 the immediate appointment of Lee Scott Golden, M.D., as an independent member of its Board of Directors. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics and has over 25 years of industry experience across cardiovascular and hematologic drug development.
His background includes senior medical roles at Espero BioPharma and Gemphire, leadership at Pfizer, Actelion, Eisai, and Mesoblast, and advisory work in coagulation sciences. Management highlighted his expertise in late-stage clinical development and regulatory pathways as aligned with Cadrenal’s goal to advance tecarfarin and its broader anticoagulation pipeline.
Cadrenal Therapeutics (Nasdaq: CVKD) reported Q3 2025 results and clinical and corporate updates on November 10, 2025. Key development milestones include cGMP manufacturing completion for tecarfarin, ongoing activities supporting a single-site U.S. Phase 2 tecarfarin study in LVAD patients with Abbott, and investigator discussions for a potential multi-site Phase 2 dialysis study.
In September 2025 Cadrenal acquired eXIthera assets, adding a Phase 2-ready IV Factor XIa inhibitor, frunexian, aimed at acute care and device-related thrombosis settings. Q3 financials: R&D $0.7M, G&A $2.0M, net loss $2.7M, cash and equivalents $3.9M, and ~2.1M shares outstanding.
Cadrenal Therapeutics (Nasdaq: CVKD), a biopharmaceutical company focused on anticoagulation therapy, will participate in the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025.
The company's webcast presentation is scheduled for 3:30 p.m. ET and will be accessible through the conference website. Management will also be available for one-on-one meetings with investors throughout the event.
Cadrenal Therapeutics (Nasdaq: CVKD) has acquired eXIthera Pharmaceuticals' portfolio of Factor XIa inhibitors, significantly expanding its anticoagulation pipeline. The acquisition includes frunexian, a Phase 2-ready intravenous Factor XIa inhibitor, and EP-7327, an IND-ready oral Factor XIa inhibitor.
The deal positions Cadrenal as the only company developing both a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, targeting the $38 billion global anticoagulation market. The acquisition terms include milestone payments up to $15 million and future royalties. Sichuan Haisco Pharmaceuticals maintains rights to frunexian in China, with Cadrenal receiving royalties on future Chinese sales.
Cadrenal Therapeutics (NASDAQ:CVKD) has reported its Q2 2025 financial results and announced strategic plans for tecarfarin clinical trials. The company will initiate trials for patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis, leveraging tecarfarin's orphan drug and fast-track designations.
Key financial metrics include R&D expenses of $1.1M (down from $1.3M in Q2 2024), G&A expenses of $2.7M (up from $1.2M), and a net loss of $3.7M (increased from $2.4M). Cash position stands at $5.6M as of June 30, 2025.
Operational highlights include successful technical transfer of tecarfarin manufacturing to a U.S. CDMO site, completion of clinical drug product manufacturing, and inclusion in Russell indexes. The company continues exploring development partnerships while focusing on addressing critical anticoagulation therapy gaps.
Cadrenal Therapeutics (Nasdaq: CVKD) has announced plans to initiate clinical trials for tecarfarin, its lead late-stage drug candidate, targeting patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis. The trials, set to begin in late 2025, will include patients both with and without atrial fibrillation (AFib).
Tecarfarin, which has received orphan drug and fast-track designations for ESKD patients with AFib, represents a potential breakthrough as a next-generation Vitamin K antagonist. The drug's unique metabolism pathway is not significantly affected by kidney impairment, addressing a critical treatment gap for dialysis patients who are typically excluded from clinical trials due to high risk profiles.
Cadrenal Therapeutics (NASDAQ: CVKD) has achieved key manufacturing milestones for tecarfarin, its lead drug candidate. The company successfully completed the technical transfer and manufacturing of tecarfarin drug substance under cGMP standards at a U.S.-based CDMO facility earlier this year. The manufacturing of the drug product candidate is currently in progress.
Tecarfarin is a novel oral vitamin K antagonist (VKA) anticoagulant designed to address unmet needs in anticoagulation therapy for patients with cardiovascular disease. The manufacturing progress represents a significant step in supporting the company's clinical development strategy.